# A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

> **NCT00243412** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** folate
- **DRUG:** methotrexate
- **DRUG:** methylprednisolone
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00243412
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243412, "A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00243412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*